UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials

Brentnall, Adam R; Cuzick, Jack; Byers, Helen; Segal, Corrinne; Reuter, Caroline; Detre, Simone; Sestak, Ivana; ... Dowsett, Mitchell; + view all (2016) Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials. Breast Cancer Research and Treatment , 158 (3) pp. 591-596. 10.1007/s10549-016-3885-x. Green open access

[thumbnail of Relationship_of_ZNF423_and_CTSO_with_breast_cancer.pdf]
Preview
Text
Relationship_of_ZNF423_and_CTSO_with_breast_cancer.pdf - Published Version

Download (494kB) | Preview

Abstract

A case–control study from two randomised breast cancer prevention trials of tamoxifen and raloxifene (P-1 and P-2) identified single-nucleotide polymorphisms (SNPs) in or near genes ZNF423 and CTSO as factors which predict which women will derive most anti-cancer benefit from selective oestrogen receptor modulator (SERM) therapy. In this article, we further examine this question using blood samples from two randomised tamoxifen prevention trials: the International Breast Cancer Intervention Study I (IBIS-I) and the Royal Marsden trial (Marsden). A nested case–control study was designed with 2:1 matching in IBIS-I and 1:1 matching in Marsden. The OncoArray was used for genotyping and included two SNPs previously identified (rs8060157 in ZNF423 and rs10030044 near CTSO), and 102 further SNPs within the same regions. Overall, there were 369 cases and 662 controls, with 148 cases and 268 controls from the tamoxifen arms. Odds ratios were estimated by conditional logistic regression, with Wald 95 % confidence intervals. In the tamoxifen arms, the per-allele odds ratio for rs8060157 was 0.99 (95 %CI 0.73–1.34) and 1.00 (95 %CI 0.76–1.33) for rs10030044. In the placebo arm, the odds ratio was 1.10 (95 %CI 0.87–1.40) for rs8060157 and 1.01 (95 %CI 0.79–1.29) for rs10030044. There was no evidence to suggest that other SNPs in the surrounding regions of these SNPs might predict response to tamoxifen. Results from these two prevention trials do not support the earlier findings. rs8060157 in ZNF423 and rs10030044 near CTSO do not appear to predict response to tamoxifen.

Type: Article
Title: Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials
Open access status: An open access version is available from UCL Discovery
DOI: 10.1007/s10549-016-3885-x
Publisher version: https://doi.org/10.1007/s10549-016-3885-x
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Breast Cancer; Randomised Prevention Trials; Single Nucleotide Polymorphisms; Stratified Medicine; Tamoxifen response
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Wolfson Inst for Biomedical Research
URI: https://discovery.ucl.ac.uk/id/eprint/10179417
Downloads since deposit
4Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item